BIT Capital’s Avalo Therapeutics AVTX Stock Holding History

BIT Capital’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,929	Closed	-$24.5K	–	111
2025 Q3	$24.5K	Buy	+1,929	New	+$16.6K	﹤0.01%	110

Other funds holding AVTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT Capital's AVTX Position: Q4 2025 in Review

BIT Capital sold out of Avalo Therapeutics (AVTX) in Q4 2025, closing a stake of 1,929 shares — an estimated $24.5K sold.

BIT Capital first reported a position in AVTX in Q3 2025 and held it in 1 quarter. The position peaked at $24.5K in Q3 2025. 84 funds tracked by Wall St. Rank hold AVTX as of Q4 2025.

BIT Capital reported no remaining Avalo Therapeutics position as of Q4 2025 after selling out during the quarter.
BIT Capital sold 1,929 Avalo Therapeutics shares in Q4 2025, an estimated $24.5K.
BIT Capital first reported a position in Avalo Therapeutics in Q3 2025 and held it in 1 quarter.
BIT Capital's Avalo Therapeutics position peaked at $24.5K in Q3 2025.
84 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2025.

Based on BIT Capital's 13F filing for Q4 2025, filed 11 Feb 2026.